This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
== Sources == Rowland, Malcolm; Tozer, N. (2010). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications (4 ed.). Philadelphia, PA: Lippincott Williams & Wilkins. ISBN 978-0-7817-5009-7. Welling, Peter G.; Tse, Francis L. S.; Dighe, Shrikant V. (1991). Pharmaceutical Bioequivalence. Drugs and the Pharmaceutical Sciences. Vol. 48. New York, NY: Marcel Dekker. ISBN 978-0-8247-8484-3. Hauschke, Dieter; Steinijans, Volker; Pigeot, Iris (2007). "Metrics to characterize concentration-time profiles in single- and multiple-dose bioequivalence studies". Bioequivalence Studies in Drug Development: Methods and Applications. Statistics in Practice. Chichester, UK: John Wiley and Sons. pp. 17–36. ISBN 978-0-470-09475-4. Retrieved 21 April 2011. Chow, Shein-Chung; Liu, Jen-pei (15 October 2008). Design and Analysis of Bioavailability and Bioequivalence Studies. Biostatistics Series. Vol. 27 (3rd ed.). FL: CRC Press. ISBN 978-1-58488-668-6.
==== Digital wholesale and B2B platforms ==== Wholesale is increasingly supported by e-procurement, B2B marketplaces, and automated order-to-cash processes (catalogs, electronic orders, invoicing, and payments). UNCTAD reports that "business e-commerce" sales grew strongly from 2016 to 2022 (with trillions of dollars in value across measured economies), reflecting the growing role of digital channels in business purchasing and selling. Artificial Intelligence (AI) has been used in B2B sourcing and procurement more recently but can still be considered in its infancy. When AI is used to address business issues, the main features of AI include increasing human efficiency and automation.
==== As a scientific standard ==== On 7 April 1795, the gram was defined in France to be equal to "the absolute weight of a volume of pure water equal to a cube of one-hundredth of a meter, and at the temperature of melting ice". For practical purposes though, a metallic reference standard was required, one thousand times more massive, the kilogram. Work was therefore commissioned to determine precisely the mass of one liter of water. In spite of the fact that the decreed definition of the gram specified water at 0 °C (32 °F)—a highly reproducible temperature—the scientists chose to redefine the standard and to perform their measurements at the temperature of highest water density, which was measured at the time as 4 °C (39 °F). The Kelvin temperature scale of the SI system was based on the triple point of water, defined as exactly 273.16 K (0.01 °C; 32.02 °F), but as of May 2019 is based on the Boltzmann constant instead. The scale is an absolute temperature scale with the same increment as the Celsius temperature scale, which was originally defined according to the boiling point (set to 100 °C (212 °F)) and melting point (set to 0 °C (32 °F)) of water. Natural water consists mainly of the isotopes hydrogen-1 and oxygen-16, but there is also a small quantity of heavier isotopes oxygen-18, oxygen-17, and hydrogen-2 (deuterium). The percentage of the heavier isotopes is very small, but it still affects the properties of water. Water from rivers and lakes tends to contain less heavy isotopes than seawater.
Type 1 and 2 diabetes was estimated to cause $10.5 billion in annual medical costs ($875 per month per diabetic) and an additional $4.4 billion in indirect costs ($366 per month per person with diabetes) in the U.S. In the United States $245 billion every year is attributed to diabetes. Individuals diagnosed with diabetes have 2.3 times the health care costs as individuals who do not have diabetes. One in ten health care dollars is spent on individuals with type 1 and 2 diabetes.
Sources: en.wikipedia.org
Nerves are responsible for controlling the contraction of muscles, determining the number, sequence and force of muscular contraction. Most movements require a force far below what a muscle could potentially generate, and nervous fatigue is seldom an issue. But, during extremely powerful contractions that are close to the upper limit of a muscle's ability to generate force, nervous fatigue (enervation) — in which the nerve signal weakens — can be a limiting factor in untrained individuals. In novice strength trainers, the muscle's ability to generate force is most strongly limited by nerve's ability to sustain a high-frequency signal. After a period of maximum contraction, the nerve's signal reduces in frequency and the force generated by the contraction diminishes. There is no sensation of pain or discomfort, the muscle appears to simply 'stop listening' and gradually cease to contract, often going backwards. Often there is insufficient stress on the muscles and tendons to cause delayed onset muscle soreness following the workout. Part of the process of strength training is increasing the nerve's ability to generate sustained, high frequency signals which allow a muscle to contract with its greatest force. This neural training can cause several weeks of rapid gains in strength, which level off once the nerve is generating maximum contractions and the muscle reaches its physiological limit. Past this point, training effects increase muscular strength through myofibrillar or sarcoplasmic hypertrophy and metabolic fatigue becomes the factor limiting contractile force.
In 2023, 88% of the Portuguese population lived in urban areas. The capital city, Lisbon, had a population of 658,236 as of 2025. It is part of Lisbon metropolitan area, the biggest metropolitan area of Portugal with 3.4 million people.
Chris Heaton-Harris, the Secretary of State for Northern Ireland, announces the deadline to call the next Northern Ireland Assembly election would be extended until 8 February to allow the DUP to hold further talks about restarting the Northern Ireland Executive. 24 January – In a BBC interview, Conservative MP Simon Clarke calls for Rishi Sunak to be ousted as prime minister, then later says he is acting alone in his comments. Retired British Army officer Colonel Tim Collins is selected to run as the UUP candidate for North Down at the next general election. Andy Street, the mayor of the West Midlands, announces that he and his Manchester counterpart, Andy Burnham, are to meet Mark Harper, the Secretary of State for Transport, to discuss proposals for a privately funded alternative to the abandoned Manchester leg of HS2. 25 January – The UK has walked away from trade deal negotiations with Canada after failing to agree on how much access UK producers should have to the Canadian cheese market. 26 January – The Crown Prosecution Service has frozen assets belonging to former Conservative peer Michelle Mone and her husband Doug Barrowman, a spokesman for the couple says. Wales's Education Minister, Jeremy Miles, criticises the way Wales' largest trade union, Unite, declared its preferred candidate for the Welsh Labour leadership election. The union held a hustings with the two candidates before announcing its support for Vaughan Gething.
== Occurrence == Trace amounts of plutonium-238, plutonium-239, plutonium-240, and plutonium-244 can be found in nature. Small traces of plutonium-239, a few parts per trillion, and its decay products are naturally found in some concentrated ores of uranium, such as the natural nuclear fission reactor in Oklo, Gabon. The ratio of plutonium-239 to uranium at the Cigar Lake Mine uranium deposit ranges from 2.4×10−12 to 44×10−12. These trace amounts of 239Pu originate in the following fashion: on rare occasions, 238U undergoes spontaneous fission, and in the process, the nucleus emits one or two free neutrons with some kinetic energy. When one of these neutrons strikes the nucleus of another 238U atom, it is absorbed by the atom, which becomes 239U. With a relatively short half-life, 239U decays to 239Np, which decays into 239Pu. Finally, exceedingly small amounts of plutonium-238, attributed to the extremely rare double beta decay of uranium-238, have been found in natural uranium samples. Due to its relatively long half-life of about 80 million years, it was suggested that plutonium-244 occurs naturally as a primordial nuclide, but early reports of its detection could not be confirmed. Based on its likely initial abundance in the Solar System, present experiments as of 2022 are likely about an order of magnitude away from detecting live primordial 244Pu. However, its long half-life ensured its circulation across the Solar System before its extinction, and indeed, evidence of the spontaneous fission of extinct 244Pu has been found in meteorites.
==== Origins of molecular biology ==== Following the rise of classical genetics, many biologists—including a new wave of physical scientists in biology—pursued the question of the gene and its physical nature. Warren Weaver—head of the science division of the Rockefeller Foundation—issued grants to promote research that applied the methods of physics and chemistry to basic biological problems, coining the term molecular biology for this approach in 1938; many of the significant biological breakthroughs of the 1930s and 1940s were funded by the Rockefeller Foundation.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.